[go: up one dir, main page]

EP1551221A4 - Compositions d'acide nucleique destinees a stimuler les reponses immunitaires - Google Patents

Compositions d'acide nucleique destinees a stimuler les reponses immunitaires

Info

Publication number
EP1551221A4
EP1551221A4 EP03763239A EP03763239A EP1551221A4 EP 1551221 A4 EP1551221 A4 EP 1551221A4 EP 03763239 A EP03763239 A EP 03763239A EP 03763239 A EP03763239 A EP 03763239A EP 1551221 A4 EP1551221 A4 EP 1551221A4
Authority
EP
European Patent Office
Prior art keywords
nucleic acid
immune responses
acid compositions
stimulating immune
stimulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03763239A
Other languages
German (de)
English (en)
Other versions
EP1551221A2 (fr
Inventor
Arthur M Krieg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coley Pharmaceutical Group Inc
Original Assignee
Coley Pharmaceutical Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coley Pharmaceutical Group Inc filed Critical Coley Pharmaceutical Group Inc
Publication of EP1551221A2 publication Critical patent/EP1551221A2/fr
Publication of EP1551221A4 publication Critical patent/EP1551221A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Zoology (AREA)
EP03763239A 2002-07-03 2003-07-03 Compositions d'acide nucleique destinees a stimuler les reponses immunitaires Withdrawn EP1551221A4 (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US39419302P 2002-07-03 2002-07-03
US39409002P 2002-07-03 2002-07-03
US39416402P 2002-07-03 2002-07-03
US39388002P 2002-07-03 2002-07-03
US39409102P 2002-07-03 2002-07-03
US394164P 2002-07-03
US394090P 2002-07-03
US394193P 2002-07-03
US394091P 2002-07-03
US393880P 2002-07-03
PCT/US2003/021113 WO2004005476A2 (fr) 2002-07-03 2003-07-03 Compositions d'acide nucleique destinees a stimuler les reponses immunitaires

Publications (2)

Publication Number Publication Date
EP1551221A2 EP1551221A2 (fr) 2005-07-13
EP1551221A4 true EP1551221A4 (fr) 2007-08-01

Family

ID=30119452

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03763239A Withdrawn EP1551221A4 (fr) 2002-07-03 2003-07-03 Compositions d'acide nucleique destinees a stimuler les reponses immunitaires

Country Status (7)

Country Link
EP (1) EP1551221A4 (fr)
JP (2) JP2005532067A (fr)
CN (1) CN1678188B (fr)
AU (1) AU2003247880B2 (fr)
CA (1) CA2494508A1 (fr)
SG (1) SG167667A1 (fr)
WO (1) WO2004005476A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2504493C (fr) 2002-11-01 2015-12-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Procede de prevention d'infections a partir d'agents de terrorisme biologique avec des oligonucleotides cpg immunostimulateurs
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
NZ575437A (en) * 2006-09-27 2012-02-24 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
CA2687535C (fr) * 2007-05-18 2017-08-22 Coley Pharmaceutical Gmbh Analogues d'oligonucleotides modifies par phosphate, presentant une activite immunostimulante amelioree
WO2009052376A1 (fr) 2007-10-18 2009-04-23 Musc Foundation For Research Development Procédés de diagnostic d'un cancer génito-urinaire
JP5589274B2 (ja) * 2007-10-25 2014-09-17 東レ株式会社 免疫誘導剤
JP5359883B2 (ja) * 2007-11-28 2013-12-04 東レ株式会社 肝炎の治療剤又は予防剤
CN101559224B (zh) * 2008-04-18 2012-07-11 北京生物制品研究所 脊髓灰质炎疫苗
EP2471926A3 (fr) * 2010-12-30 2012-07-11 Intervet International BV Oligodésoxynucléotides immunostimulateurs
MX373641B (es) 2011-04-29 2020-05-04 Selecta Biosciences Inc Nanoportadores sintéticos tolerogénicos para la terapia contra alergias.
EP2714908B1 (fr) * 2011-05-26 2018-04-18 Intervet International B.V. Oligodésoxynucléotides immunostimulateurs
CN105283175A (zh) 2013-05-03 2016-01-27 西莱克塔生物科技公司 用于降低的或增强的药效学作用的致耐受性合成纳米载体和治疗性大分子
PT3542819T (pt) * 2013-05-14 2021-10-14 Zoetis Services Llc Composições de vacina inovadoras que compreendem oligonucleótidos imunoestimulantes
KR20170045344A (ko) 2014-09-07 2017-04-26 셀렉타 바이오사이언시즈, 인크. 항-바이러스 전달 벡터 면역 반응을 약화시키기 위한 방법 및 조성물
KR20170098957A (ko) * 2015-01-16 2017-08-30 시티 오브 호프 세포 침투성 항체
EP3490598A1 (fr) * 2016-07-26 2019-06-05 Bayer Animal Health GmbH Augmentation de la fertilité chez les espèces bovines
JP7523909B2 (ja) 2017-03-11 2024-07-29 セレクタ バイオサイエンシーズ インコーポレーテッド 抗炎症剤および免疫抑制剤を含む合成ナノキャリアによる組み合わせ処置に関連する方法および組成物
CN113440609A (zh) * 2020-03-27 2021-09-28 北京市农林科学院 一种双链rna复合物autp及其在疫苗制备中的应用
CN113493790A (zh) * 2020-04-01 2021-10-12 南京华普生物技术股份有限公司 具有免疫调节功能的CpG ODN及其应用
CN117947031B (zh) * 2024-01-30 2024-12-24 中国医学科学院基础医学研究所 Cgt-odn在免疫调节中的应用
CN117925840A (zh) * 2024-01-30 2024-04-26 中国医学科学院基础医学研究所 Slfn11在cgt-odn治疗癌症疗效预测中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001022972A2 (fr) * 1999-09-25 2001-04-05 University Of Iowa Research Foundation Acides nucleiques immunostimulateurs
WO2004016805A2 (fr) * 2002-08-19 2004-02-26 Coley Pharmaceutical Group, Inc. Acides nucléiques immunostimulants
WO2004039829A2 (fr) * 2002-10-29 2004-05-13 Coley Pharmaceutical Group, Ltd. Techniques et produits relatifs au traitement et a la prevention de l'infection par le virus de l'hepatite c
WO2004087203A2 (fr) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Formulations de type huile-dans-l'eau a base d'acides nucleiques immunostimulateurs, et procedes d'utilisation associes
WO2004094671A2 (fr) * 2003-04-22 2004-11-04 Coley Pharmaceutical Gmbh Procedes et produits pour identifier et evaluer des ligands des tlr

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP2085090A3 (fr) * 1997-06-06 2012-05-02 The Regents of the University of California Inhibiteurs de l'activité de séquences immunostimulatrices de l'ADN
ATE305507T1 (de) * 1998-05-14 2005-10-15 Coley Pharm Gmbh Verfahren zur regulierung der hematopoiese mit hilfe von cpg oligonukleotide
IL139813A0 (en) * 1998-05-22 2002-02-10 Loeb Health Res Inst At The Ot Methods and products for inducing mucosal immunity
WO2000067787A2 (fr) * 1999-05-06 2000-11-16 The Immune Response Corporation Compositions et procedes immunogenes anti-vih
AU783118B2 (en) * 1999-09-27 2005-09-29 Coley Pharmaceutical Gmbh Methods related to immunostimulatory nucleic acid-induced interferon
DE60126593T2 (de) * 2000-04-06 2007-10-31 Epigenomics Ag Diagnose von mit apoptose assoziierten erkrankungen mittels ermittlung des methylierungszustandes von apoptose-assozierten genen
WO2002002806A2 (fr) * 2000-06-30 2002-01-10 Epigenomics Ag Procede et acides nucleiques pour analyse de methylation pharmacogenomique
AU1218802A (en) * 2000-09-01 2002-03-13 Epigenomics Ag Method for determining the degree of methylation of defined cytosines in genomicdna in the sequence context 5'-cpg-3'
AU2002331643B2 (en) * 2001-08-17 2007-10-11 Coley Pharmaceutical Gmbh Combination motif immune stimulatory oligonucleotides with improved activity

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001022972A2 (fr) * 1999-09-25 2001-04-05 University Of Iowa Research Foundation Acides nucleiques immunostimulateurs
WO2004016805A2 (fr) * 2002-08-19 2004-02-26 Coley Pharmaceutical Group, Inc. Acides nucléiques immunostimulants
WO2004039829A2 (fr) * 2002-10-29 2004-05-13 Coley Pharmaceutical Group, Ltd. Techniques et produits relatifs au traitement et a la prevention de l'infection par le virus de l'hepatite c
WO2004087203A2 (fr) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Formulations de type huile-dans-l'eau a base d'acides nucleiques immunostimulateurs, et procedes d'utilisation associes
WO2004094671A2 (fr) * 2003-04-22 2004-11-04 Coley Pharmaceutical Gmbh Procedes et produits pour identifier et evaluer des ligands des tlr

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2004005476A2 *

Also Published As

Publication number Publication date
SG167667A1 (en) 2011-01-28
CA2494508A1 (fr) 2004-01-15
EP1551221A2 (fr) 2005-07-13
WO2004005476A2 (fr) 2004-01-15
JP2009132737A (ja) 2009-06-18
JP2005532067A (ja) 2005-10-27
AU2003247880B2 (en) 2010-09-02
CN1678188A (zh) 2005-10-05
CN1678188B (zh) 2012-10-10
AU2003247880A1 (en) 2004-01-23
WO2004005476A3 (fr) 2004-05-21

Similar Documents

Publication Publication Date Title
EP1551221A4 (fr) Compositions d'acide nucleique destinees a stimuler les reponses immunitaires
IL174848A0 (en) Nucleic acid constructs
TWI345971B (en) Nutritional compositions
IL164664A0 (en) Oligonucleotide compositions and their use for themodulation of immune responses
IL166376A0 (en) Immunostimulatory nucleic acids
IL208316A (en) Compound comprising nucleic acid strands
AU2003270310A8 (en) Compositions and methods for synthesizing nucleic acids
GB0319874D0 (en) Novel formulation
GB0317044D0 (en) Nucleic acid isolation
EP1617872A4 (fr) Procedes et compositions permettant de renforcer une reponse immune
GB2417488B (en) Erucamide-free slip compositions
GB0210766D0 (en) Isolating nucleic acid
EP1644081A4 (fr) Connecteur de defibrillation a configurations multiples
AU2003284127A8 (en) Nucleic acid supported protein complementation
GB0606187D0 (en) Acid containing oxaliplatin formulations
AU2003232036A8 (en) Nanoarchaeum nucleic acid molecule
GB0209382D0 (en) Isolating nucleic acid
HK1077474A (en) Nucleic acid compositions for stimulating immune responses
GB2401551B (en) Stimulation aid
GB0314605D0 (en) Nucleic acid preparation
AU2003222173A1 (en) Nucleic acid compositions and methods for use
SI1604683T1 (sl) Vakcinski pripravki na gangliozidni osnovi za subkutano dajanje
EP1696034A4 (fr) Methode de transfert d'acide nucleique
GB0226717D0 (en) DNA vaccination
GB0322764D0 (en) Control of immune responses

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050203

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1077474

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20070704

17Q First examination report despatched

Effective date: 20071010

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1077474

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140201